For research use only. Not for therapeutic Use.
Lusutrombopag（Cat No.:I000448）is an oral thrombopoietin receptor agonist used to treat thrombocytopenia in adults with chronic liver disease who are scheduled for a medical procedure. By selectively stimulating the thrombopoietin receptor on megakaryocytes, Lusutrombopag promotes platelet production, increasing platelet counts and reducing the risk of bleeding during invasive procedures. Its targeted action minimizes the need for platelet transfusions, offering a safer and more convenient option for managing low platelet levels in patients with liver disease. Lusutrombopag provides an effective, non-invasive treatment for improving procedural safety in thrombocytopenic patients.
| Catalog Number | I000448 |
| CAS Number | 1110766-97-6 |
| Synonyms | (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid |
| Molecular Formula | C29H32Cl2N2O5S |
| Purity | 97% |
| Target | MPL |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | EC50: 84.0 nmol/L(Ba/F3-hMpl cells) |
| IUPAC Name | (E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid |
| InChI | InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1 |
| InChIKey | NOZIJMHMKORZBA-KJCUYJGMSA-N |
| SMILES | CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\C)/C(=O)O)Cl |
| Reference | [1]. Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8. |
